Antibiotic Treatment of Severe Infections with Multiresistant Bacteria.

TL;DR

Clinical practice guideline recommends pathogen-directed antibiotic treatment for severe multidrug-resistant organism (MDRO) infections, with specific first-line agents (ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam) for non-metallo-β-lactamase producers and alternative agents for resistant strains.

Key findings

• Pathogen identification and sensitivity testing are essential; metallo-β-lactamase detection/exclusion is critical for Gram-negative MDRO management
• First-line agents for non-metallo-β-lactamase MDRO: ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam; cefiderocol or aztreonam-avibactam for resistant strains
• DTR-PA treatment: ceftolozan-tazobactam preferred; CRAB: cefiderocol recommended; MRSA bloodstream infection: daptomycin or vancomycin; MRSA pneumonia: linezolid or vancomycin
• Reserve antibiotics should be used selectively as part of antimicrobial stewardship; treatment tailored to site of infection, resistance mechanism, and clinical situation

Why this matters at the bedside

Directly applicable to clinicians managing severe infections with multidrug-resistant organisms; provides evidence-based guidance on antibiotic selection across major MDRO pathogens (CRE, DTR-PA, CRAB, MRSA, VRE) to optimize treatment outcomes and reduce resistance development.